Export

EN
FR
Daclatasvir
Essential medicine status
Section:
6. Anti-infective medicines 6.4. Antiviral medicines 6.4.4. Antihepatitis medicines 6.4.4.2. Medicines for hepatitis C 6.4.4.2.1. Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
ATC codes: J05AP07
EMLc
Indication
Chronic hepatitis C ICD11 code: 1E91.1
INN
Daclatasvir
Medicine type
Chemical agent
List type
Core (EML)
(EMLc)
Additional notes
Pangenotypic when used in combination with sofosbuvir.
Formulations
Oral > Solid > tablet: 30 mg (as dihydrochloride) ; 60 mg (as dihydrochloride)
EML status history
First added in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2021 (TRS 1035)
Changed in 2025 (TRS 1064)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations
Pangenotypic direct-acting antiviral combinations
Therapeutic alternatives limitations for EMLc
Pangenotypic direct-acting antiviral combinations
Patent information
Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Wikipedia
Daclatasvir
DrugBank
Daclatasvir
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.